Company profile
MeiraGTx Holdings plc
NASDAQ:MGTXBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05603312 | phase1_2 | completed | 2022-10-05 | 2024-09-06 | MeiraGTx, LLC | A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants |
| NCT04043104 | phase1 | completed | 2019-06-30 | 2023-03-28 | MeiraGTx UK II Ltd | A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia |
| NCT05926765 | phase2 | active_not_recruiting | 2023-06-13 | 2027-06-01 | MeiraGTx, LLC | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia |
| NCT02781480 | phase1_2 | completed | 2016-04-01 | 2018-12-01 | MeiraGTx UK II Ltd | Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) |
| NCT03758404 | phase1_2 | completed | 2019-08-12 | 2021-06-10 | MeiraGTx UK II Ltd | Gene Therapy for Achromatopsia (CNGA3) |
FDA applications (0)
No records yet.